Attached files
| file | filename |
|---|---|
| EX-99.2 - EX-99.2 - Unilife Corp | d786787dex992.htm |
| 8-K - FORM 8-K - Unilife Corp | d786787d8k.htm |
Exhibit 99.1
Unilife Corporation Announces Financial Results
For the Fourth Quarter and Full Fiscal Year 2014
York, PA (September 9, 2014) Unilife Corporation (“Unilife” or “Company”) (NASDAQ:UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the fiscal fourth quarter and full fiscal year ending June 30, 2014.
Recent Highlights
| • | Revenue for the Full Fiscal Year of 2014 was $14.7 million, an increase of approximately $12 million or over 400% compared to the prior year. Deferred revenue, which is cash that has been collected and is expected to be recognized within the coming 24 months, for the Full Fiscal Year of 2014 increased to $13.3 million. |
| • | Cash receipts from customers were $23.7 million for the Full Fiscal Year of 2014, an increase of $22.5 million compared to the prior year. |
| • | The net operating cash flow loss was narrowed by 20% over the year before, despite a significant increase in R&D investments. Over half of the Company’s total annual operating expenses were invested in R&D during the Full Fiscal Year of 2014. |
| • | At the end of the fourth quarter of Fiscal Year 2014, Unilife had 12 active customer programs, an increase of two programs since the end of the prior quarter, across all six of its product platforms. |
| • | Since July 1, 2014, Unilife has commenced commercial sales of the Unifill® syringe utilizing an existing commercial manufacturing line. Commercial sales of other products from the Unifill family, including the Unifill Finesse® and the Unifill Nexus™, are scheduled to commence during the middle of the 2015 fiscal year on additional manufacturing lines that are either in the process of being configured or are now operational and in the process of being qualified. |
Mr. Alan Shortall, Chairman and CEO of Unilife, commented: “Fiscal 2014 was a year of rapid growth in revenue, customers, supply agreements and production capabilities. Having made significant investments in R&D during the last three years, we have achieved a critical mass in product range, capabilities and industry expertise. Those investments are now generating revenue at an attractive growth rate as we enter into and execute upon supply agreements with a growing number of pharmaceutical customers.”
“During Fiscal Year 2015, we look forward to achieving significant growth in revenue via commercial sales, customization fees and upfront payments from a multitude of customers and active programs. In parallel, we expect to increase capital expenditures in response to growing customer demand while moderating our investments in R&D and keeping SG&A largely stable. We also look forward to completing a number of additional significant supply agreements, which have taken longer than originally anticipated to complete but are now approaching the finish line. Based upon current cash on hand including the recently completed ATM, along with scheduled payments under existing and imminent agreements, we feel confident that we will have sufficient cash to offset our full year operating activities for fiscal 2015,” Mr. Shortall concluded.
Unilife Corporation
250 Cross Farm Lane, York, PA 17406 T + 1 717 384 3400 F + 717 384 3401 E info@unilife.com W www.unilife.com
Financial Results for the Full Fiscal Year 2014
Revenue for the Full Fiscal Year of 2014 was $14.7 million, compared to $2.7 million for the same period in 2013. Deferred revenue increased to $13.3 million as of June 30, 2014. The Company’s net loss for the Full Fiscal Year of 2014 was $57.9 million, or $0.59 per share, compared to a net loss of $63.2 million, or $0.78 per share, for fiscal year 2013.
Adjusted net loss for the Full Fiscal Year of 2014 was $38.8 million, or $0.40 per share, compared to $38.0 million or $0.47 per share for the prior year. Adjusted net loss excludes non-cash share-based compensation expense, depreciation and amortization, interest expense and the change in fair value of financial instruments.
Unilife reported $10.8 million in total cash and restricted cash at the end of Fiscal Year 2014, which ended on June 30, 2014. This does not include $12.4 million in net proceeds generated through the completion of our ATM facility in August 2014, or other cash receipts generated by customers since July 1, 2014.
Conference Call Information
Management has scheduled a conference call for 4:30 p.m. U.S. EDT on Tuesday, September 9, 2014, (Wednesday, September 10, 2014 at 6:30 a.m. AEST), to review the Company’s financial results, customer partnerships and future outlook. The conference call and accompanying slide presentation will be broadcast over the Internet as a “live” listen-only Webcast. An archive of the presentation and webcast will be available for 30 days after the call. To listen, please go to: http://ir.unilife.com/events.cfm.
About Unilife Corporation
Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife’s broad portfolio of proprietary technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Each of these innovative and highly differentiated platforms can be customized to address specific customer, drug and patient requirements. Unilife’s global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.
Forward-Looking Statements
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.
Non-GAAP Financial Measures
U.S. securities laws require that when we publish any non-GAAP financial measure, we disclose the reason for using the non-GAAP measure and provide reconciliation to the most directly comparable GAAP measure. The presentation of adjusted net income (loss) and adjusted net income (loss) per share are non-GAAP measures. Adjusted net income (loss) represents net income (loss) calculated in accordance with U.S. GAAP as adjusted for the impact of share-based compensation expense, depreciation and amortization and interest expense.
Unilife Corporation
250 Cross Farm Lane, York, PA 17406 T + 1 717 384 3400 F + 717 384 3401 E info@unilife.com W www.unilife.com
Management believes the presentation of adjusted net income (loss) and adjusted net income (loss) per share provides useful information because these measures enhance its own evaluation, as well as investor’s understanding, of the Company’s core operating and financial results. Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation of net income (loss) to adjusted net income (loss) is included in the attached table.
General: UNIS-G
| Investor Contacts (US): | Analyst Enquiries | Investor Contacts (Australia) | ||
| Todd Fromer / Garth Russell | Leigh Salvo | Jeff Carter | ||
| KCSA Strategic Communications | Westwicke Partners | Unilife Corporation | ||
| P: + 1 212-682-6300 | P: + 1 415-513-1281 | P: + 61 2 8346 6500 | ||
Unilife Corporation
250 Cross Farm Lane, York, PA 17406 T + 1 717 384 3400 F + 717 384 3401 E info@unilife.com W www.unilife.com
UNILIFE CORPORATION AND SUBSIDIARIES
Consolidated Balance Sheets
(unaudited)
| June 30, | ||||||||
| 2014 | 2013 | |||||||
| (in thousands, except share data) | ||||||||
| Assets | ||||||||
| Current Assets: |
||||||||
| Cash and cash equivalents |
$ | 8,368 | $ | 5,736 | ||||
| Restricted cash |
2,400 | 2,400 | ||||||
| Accounts receivable |
1,860 | 654 | ||||||
| Inventories |
142 | 71 | ||||||
| Prepaid expenses and other current assets |
1,108 | 409 | ||||||
|
|
|
|
|
|||||
| Total current assets |
13,878 | 9,270 | ||||||
| Property, plant and equipment, net |
54,588 | 46,106 | ||||||
| Goodwill |
11,830 | 11,498 | ||||||
| Intangible assets, net |
18 | 23 | ||||||
| Other assets |
1,454 | 1,504 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 81,768 | $ | 68,401 | ||||
|
|
|
|
|
|||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current Liabilities: |
||||||||
| Accounts payable |
$ | 3,583 | $ | 3,428 | ||||
| Accrued expenses |
3,339 | 2,444 | ||||||
| Current portion of long-term debt |
613 | 3,826 | ||||||
| Deferred revenue |
717 | 3,010 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
8,252 | 12,708 | ||||||
| Long-term debt, less current portion |
54,835 | 20,045 | ||||||
| Deferred revenue |
12,550 | 50 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
75,637 | 32,803 | ||||||
|
|
|
|
|
|||||
| Stockholders’ Equity: |
||||||||
| Preferred stock, $0.01 par value, 50,000,000 shares authorized as of June 30, 2014; none issued or outstanding as of June 30, 2014 and 2013 |
— | — | ||||||
| Common stock, $0.01 par value, 250,000,000 shares authorized as of June 30, 2014; 103,617,278 and 95,602,558 shares issued, and 103,588,608 and 95,573,888 shares outstanding as of June 30, 2014 and 2013, respectively |
1,036 | 956 | ||||||
| Additional paid-in-capital |
296,169 | 268,157 | ||||||
| Accumulated deficit |
(293,731 | ) | (235,832 | ) | ||||
| Accumulated other comprehensive income |
2,797 | 2,457 | ||||||
| Treasury stock, at cost, 28,670 shares as of June 30, 2014 and 2013 |
(140 | ) | (140 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
6,131 | 35,598 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 81,768 | $ | 68,401 | ||||
|
|
|
|
|
|||||
Unilife Corporation
250 Cross Farm Lane, York, PA 17406 T + 1 717 384 3400 F + 717 384 3401 E info@unilife.com W www.unilife.com
UNILIFE CORPORATION AND SUBSIDIARIES
Consolidated Statements of Operations
(unaudited)
| Three Months Ended | Year Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| (in thousands, except per share data) | ||||||||||||||||
| Revenue |
$ | 6,546 | $ | 667 | $ | 14,689 | $ | 2,743 | ||||||||
| Cost of product sales |
— | 1 | — | 128 | ||||||||||||
| Research and development |
11,887 | 6,545 | 34,111 | 21,749 | ||||||||||||
| Selling, general and administrative |
8,022 | 10,278 | 27,894 | 32,437 | ||||||||||||
| Depreciation and amortization |
1,011 | 5,484 | 4,079 | 9,487 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
20,920 | 22,308 | 66,084 | 63,801 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Operating loss |
(14,374 | ) | (21,641 | ) | (51,395 | ) | (61,058 | ) | ||||||||
| Interest expense |
1,692 | 540 | 7,332 | 2,392 | ||||||||||||
| Interest income |
(3 | ) | (6 | ) | (20 | ) | (54 | ) | ||||||||
| Other income |
(200 | ) | (198 | ) | (208 | ) | (198 | ) | ||||||||
| Change in fair value of financial instruments |
(600 | ) | — | (600 | ) | — | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss |
$ | (15,263 | ) | $ | (21,977 | ) | $ | (57,899 | ) | $ | (63,198 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss per share: |
||||||||||||||||
| Basic and diluted net loss per share |
$ | (0.15 | ) | $ | (0.25 | ) | $ | (0.59 | ) | $ | (0.78 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
Unilife Corporation
250 Cross Farm Lane, York, PA 17406 T + 1 717 384 3400 F + 717 384 3401 E info@unilife.com W www.unilife.com
UNILIFE CORPORATION AND SUBSIDIARIES
Reconciliation of Non-GAAP Measure
(unaudited)
| Three Months Ended | Year Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| (in thousands, except per share data) | ||||||||||||||||
| Net loss |
$ | (15,263 | ) | $ | (21,977 | ) | $ | (57,899 | ) | $ | (63,198 | ) | ||||
| Share-based compensation expense |
1,441 | 6,089 | 8,316 | 13,287 | ||||||||||||
| Depreciation and amortization |
1,011 | 5,484 | 4,079 | 9,487 | ||||||||||||
| Interest expense |
1,692 | 540 | 7,332 | 2,392 | ||||||||||||
| Change in fair value of financial instruments |
(600 | ) | — | (600 | ) | — | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted net loss |
$ | (11,719 | ) | $ | (9,864 | ) | $ | (38,772 | ) | $ | (38,032 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted net loss per share – diluted |
$ | (0.12 | ) | $ | (0.11 | ) | $ | (0.40 | ) | $ | (0.47 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
Unilife Corporation
250 Cross Farm Lane, York, PA 17406 T + 1 717 384 3400 F + 717 384 3401 E info@unilife.com W www.unilife.com